Published in Hepatitis Weekly, June 20th, 2005
"A 59-year-old Caucasian suffering from chronic hepatitis C started daily subcutaneous self-infections of interferon alfacon-1 (consensus interferon) according to the protocol of a randomized multicenter study. At week 10, he developed painful erythematous lesions at two injection sites," scientists writing in the European Journal of Medical Research report.
"Consensus interferon dosage was reduced, and eventually, the lesions healed with small areas of scarring due to central necrosis. At week 51, again large areas of erythematous thickened skin arose at two other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly